Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
2
33%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Other(2)

Detailed Status

unknown2
Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (50.0%)
Phase 32 (33.3%)
Phase 41 (16.7%)

Trials by Status

unknown233%
completed233%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_4

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

NCT07281014
recruitingphase_3

Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

NCT05230901
unknownphase_2

Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

NCT04327232
completedphase_2

Spironolactone in Adult Congenital Heart Disease

NCT01069510
completedphase_2

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

NCT02585843
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07281014Phase 4

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

Recruiting
NCT05230901Phase 3

Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

Recruiting
NCT04327232Phase 2

Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

Unknown
NCT01069510Phase 2

Spironolactone in Adult Congenital Heart Disease

Completed
NCT02585843Phase 2

Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance

Completed
NCT03551548Phase 3

Spironolactone and Perioperative Atrial Fibrillation Occurrence in Cardiac Surgery Patients.

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6